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STATUS OF BROMETHALIN OUTSIDE THE UNITED STATES
S.R. SPAULDING, Ciba-Geigy Animal Health/Hygiene, CH-4002 Basel, Switzerland.
H. SPANNRING, Ciba-Geigy Agricultural Research Centre, St. Aubin, Switzerland.

ABSTRACT: Bromethalin has been extensively researched over the past decade in the United States, Switzerland, England,
Denmark, and France. United States EPA registrations were received in 1982 and commercial pelleted formulations
containing 0.01% bromethalin were developed and introduced in the USA by Ralston Purina (ASSAULT1*) in 1985 and
Velsicol (VENGEANCE1*) in 1986. Ciba-Geigy is currently developing new formulations under the tradename DORATIDR
for use outside the United States. Bromethalin acute toxicity and 14-day subchronic studies are reviewed and data from
recently completed 90-day subchronic studies required for registration outside the US are presented. Pharmacodynamic
studies have shown that bromethalin acts as an uncoupler of oxidative phosphorylation, thus interrupting the vital production
of ATP necessary to maintain essential metabolic functions. Laboratory and field trial data are presented from Switzerland,
France, England, and Denmark that indicate the effectiveness of new bromethalin formulations against anticoagulant
resistant and susceptible rodents. A comparative rodenticide pen testing system is described from which test results
confirm bromethalin's quick action and feed consumption efficiency when compared to second-generation
anticoagulants.
Proc. Vertebr. Pest Conf. (A.C. Ciabb and R.E. Marsh, Eds.),
Printed at Univ. of Calif., Davis. 13:64-69, 1988

INTRODUCTION
The worldwide development of bromethalin has been an
expensive and lengthy process lasting over a decade. It has
involved the dedicated work of people from a variety of
disciplines including chemists, biologists, toxicologists,
formulation scientists, regulatory specialists, and marketers.
The search for a novel rodenticide with a mode of action
different from anticoagulants began in the mid-1970's when
leads from a fungicide screening program at Lilly Research
Laboratories indicated the rodenticidal potential of a group of
compounds classified as diphenylamines (Dreikorn and
O'Doherty 1984). After several years of screening and structure-activity relation tests, bromethalin was identified as the
compound with the greatest biological potential. At the 1979
British Crop Protection Conference, Dreikorn (1979) presented the first biological results from laboratory tests with
white rats and mice. Biological and toxicological testing
continued at Lilly until sufficient data were assembled to
submit an application for an Experimental Use Permit (EUP).
In 1980, the EUP was issued by the Environmental Protection
Agency (EPA) and a field trial program was initiated in
conjunction with the Center for Environmental Research at
Bowling Green State University. By the end of 1981, 17
successful field trials in Norway rat and house mouse infested
sites were completed and the EPA granted bromethalin
registration for use in and around buildings in 1982.
Marketing rights were subsequently licensed by Eli Lilly
to Ralston Purina and Velsicol in the United States and CibaGeigy for all countries outside the United States. Ciba-Geigy
initiated development in 1984 under the tradename DORATID1*. During the following year, ASSAULT1* was introduced
into U.S. markets by Ralston Purina, and Velsicol followed
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in 1986 with the introduction of Vengeance. Over the past 4
years, Ciba-Geigy has focused on formulation development
of grain-based baits and a bonded weather-resistant block, as
well as conducting several additional toxicology studies
required to meet European registration requirements. This
work is now coming to an end and registration was initiated
in 1988 in selected European countries.
It is the intent of this paper to review the status of
bromethalin and to discuss efficacy and toxicology studies
conducted outside the United States over the past 4 years.
REVIEW OF SELECTED BROMETHALIN TOXICOLOGICAL PROPERTIES
Toxicological aspects of bromethalin have been previously reviewed by Jackson et al. (1982), Spaulding et al.
(1985), and Spaulding (1987). This brief review of toxicological data focuses on acute and subchronic toxicity and
aspects related to pharmacodynamics, pharmacokinetics,
and metabolism.
Acute Toxicitv
Bromethalin acute LD50 values for the active ingredient
in target and non-target species range from 1.8 mg/kg (cat) to
13.0 mg/kg (rabbit). LD50's of 2.3,6.7, and 6.6 mg/kg have
been determined for the Norway rat, house mouse, and roof
rat, respectively. The acute LD50 of the 0.01% finished bait
is >2000 mg/kg.
Subchronic Toxicitv
Subchronic and chronic toxicity tests with pesticides are
designed to assess the toxicity and human carcinogenicity
risk to humans in prolonged exposure situations. The EPA
required only 14-day feeding studies with bromethalin to

support registration in the United States; however, 90-day
feeding studies were required for registration in several
European countries. While these 90-day tests are certainly
applicable in the case of herbicides and insecticides applied
to crops, the scientific value of these studies with rodenticides
is questionable due to completely different use patterns.
Rodenticides are applied in discrete locations in relatively
small quantities; therefore, the potential for human exposure
or food contamination is minimal.
In several early toxicity studies with bromethalin (van
Lieretal. 1980, van Lier and Ottosen 1981), histopathological signs of toxicity indicated vacuolation of the white matter
of the brain and spinal cord, which appeared as a spongy
degeneration. To determine whether this spongy degeneration was a reversible phenomenon, two 14-day subchronic
reversibility studies were undertaken (van Lier et al. 1980,
van Lier and Cherry 1988). Rats were dosed with 0,0.5,2 or
8 ppm bromethalin in one study and 0, 1, 3, and 5 ppm
bromethalin in a second study. Brain, spinal cord and sciatic
nerve tissues were examined histologically over an 8-week
recovery period. Behavior and motor coordination were
measured in the second study using a rotorod. All rats given
8 ppm bromethalin died during treatment or were killed when
moribund. Leg weakness and depressed motor function were
observed by day 7 in rats given 5 ppm bromethalin. Electron
and light microscopic examination of rat tissues taken at
various times during these studies demonstrated that the
primary lesions which occurred were spongy degeneration of
the CNS white matter. However, the incidence of spongy
degeneration decreased sharply at two and four weeks posttreatment and was not evident at eight weeks posttreatment,
demonstrating the reversibility of these lesions. Furthermore,
histological examination of tissues revealed no evidence of
cell necrosis.
In order to conduct 90-day subchronic toxicity studies
with inherently toxic rodenticides, extremely low doses must
be administered in order to keep test animals alive throughout
the 90-day test period. These doses were established for
bromethalin subchronic studies by conducting 4-week pilot
studies first with rats and dogs. In definitive studies (CibaGeigy, unpubl. rept.), rats and dogs were dosed with 0,5,25,
125, and 200 (dogs only) mcg/kg bromethalin daily over 90
days.Lesions were evident only atdosesof > 125 mcg/kgand
were characterized by the typical spongy degeneration of
CNS white matter seen in the 14-day studies. Even under
extended subchronic exposure, a "no observable effect level"
(NOEL) of 25 mcg/kg was demonstrated in rats and dogs.
Pharmacodvnamics/Pharmacokinetics/Metabolism
Several studies have been conducted to investigate the
mechanism of action, metabolism, tissue distribution and
excretion of bromethalin in laboratory rats. Van Lier and
Cherry (1988) recently described the mechanism of action of
bromethalin. Based upon their results from several mechanistic studies, the following mode of bromethalin toxicity is
proposed. Upon ingestion, bromethalin is metabolized to
desmethyl bromethalin which uncouples oxidative
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phosphorylation in the mitochondria. The sodium/potassium
gradient normally maintained by sodium-potassium ATPase
is weakened, and fluid builds up in the cell. While most
tissues and organs can expand slightly to accommodate this
effect, a fluid build-up inside the central nervous system leads
to increased pressure on nerve axons. Demyelination occurs
and nerve impulse transmission is reduced. In the lethally
intoxicated animal, this leads to inadequate transmission to
respiratory centers with ultimate respiratory arrest and death.
The entire process is dose-dependent and death generally
occurs from 12-72 hours following ingestion.
Studies with radio-labelled bromethalin have provided
insights into the pharmacokinetic and metabolic aspects of
bromethalin (van Lier and Ottosen 1981, van Lier and Cherry
1988). One study using radio-labeled bromethalin resulted
in disappearance of radiocarbon from plasma at a rate which
indicated a half-life of about 135 hours. Other studies using
radio-labeled bromethalin indicated excretion is primarily
through the feces and that bromethalin is absorbed after oral
administration and distributed primarily to the fat, liver,
gastrointestinal tract, adrenals, ovaries and thyroid tissues.
LABORATORY EFFICACY STUDIES
Laboratory choice tests were conducted with a variety of
0.01% bromethalin grain-based and weather-resistant
bonded block formulations using anticoagulant susceptible
and resistant Rattus norvegicus and Mus musculus. The
studies were conducted at the following international research institutes:
1. Ciba-Geigy Agricultural Research Centre - Switzerland
2. INRA, Laboratoire de la Faune Sauvage - France
3. Danish Pest Infestation Laboratory - Denmark
4. MAFF Tollworth Laboratories -U.K. Ministry of Agriculture, Fisheries and Food
Data from the Ciba-Geigy Agricultural Research Centre
have been published in part by Spaulding (1987).
A pooled data summary of choice tests with bromethalin
grain-based formulations using individually-caged wild R.
norvegicus is presented in Table 1. A total of 422 rats were
used in 27 different tests. Formulations included 0.01%
bromethalin whole oats and wheat, cracked or pinhead oats,
or oat flakes. Average percent mortality of 97% (range 94100%) was achieved within an average of 2.3 days (range 1.44.0 days) following ingestion of bromethalin baits. Formulations containing bromethalin were consumed an average of
48% (range 30-71%) of the time compared to untreated
alternative diets.
A pooled data summary of choice tests with bromethalin
weather-resistant block formulations using individuallycaged R. norvegicus is presented in Table 2. A total of 145 rats
were used in 11 different tests. Formulations consisted of
whole wheat or oats or cracked maize impregnated with
0.01% bromethalin and bonded together in a patented process. Laboratory tests have shown this formulation to be highly
palatable to rats and resistant to moisture and heat. Average
percent mortality of 96% (range 83-100%) was achieved
within an average of 3.5 days (2.1-4.6 days) following

Table 1: Choice tests with 0.01% Bromethalin Grain
Formulations Against Individually-Caged R. norvegicus.

Table 2. Choice Tests with 0.01% Bromethalin WeatherResistant Block Formulations Against Individually-Caged
R. norvegicus.

Table 3. Choice Tests with 0.01 % Bromethalin Grain Formulations Against Family Groups of M- musculus

ingestion of the bromethalin blocks. Blocks containing bromethalin were consumed an average of 60% (range 47-82%) of
the time compared to untreated alternative blocks.
A pooled data summary of choice tests with bromethalin
grain-based formulations using family groups (8-20 mice/
group) of wild M- musculus is presented in Table 3. Formulations included 0.01% bromethalin canary seed, cracked
oats, or oat flakes. A total of 326 mice were used in 20
different tests. Average percent mortality of 97% (range 92100%) was achieved within an average of 2.3 days (range 1.52.8 days) following ingestion of bromethalin baits. Formulations containing bromethalin were consumed an average of
59% (range 37-88%) of the time compared to untreated
alternative diets.
A pooled data summary of laboratory tests with bromethalin grain-based formulations using anticoagulantresistant R. norvegicus and M- musculus is presented in Table
4. A total of 170 resistant rodents were tested at research
institutes in France, England, and the United States. The R.

'Source:
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1. Ciba-Geigy Unpublished Report
2. Grolleau. 1987. Proceedings Rome EPPO/FA Conference
on Rodents
3. Lund. 1986. Unpublished Data

Table 4. Laboratory Tests with 0.01% Bromethalin Grain
Formulations Using Anticoagulant-Resistant R. norvegicus
(RN) and M- musculus (MM).
N
Bromethalin MortCountry*** Species (# Tests) Consumption ality

Days to
Death

sumption ranged from 98 to 100% with 3 to 16 days of
exposure to bromethalin baits. One hundred-fifty (150)
mouse carcasses were recovered during the trial in France.
There were no incidents of primary or secondary poisoning
to non-target species in these trials.
Table 5. Field Trials with 0.005% and 0.01% Bromethalin
Grain Formulations Against Infestations of R. norvegicus.

norvegicus tested in France were determined resistant to
bromadiolone. Average percent mortality of 92% (range 80100%) was achieved within an average of 2.9 days (1.6-4.0
days) following ingestion of bromethalin baits. Formulations
containing bromethalin were consumed an average of 45%
(range 30-63 %) of the time compared to untreated alternative
diets.
FIELD EFFICACY TRIALS
Seventeen (17) field trials were completed with 0.005%
bromethalin EPA baits in primarily rural sites such as livestock barns, poultry farms and storage buildings in 5 geographically different regions of the United States (Jackson et
al. 1982, Spaulding et al. 1985). Average percent reduction
in rodent activity in these trials ranged from 90-98% in 8 R.
norvegicus tests and from 85-99% in 9 M-musculus tests.
Bromethalin treatment periods ranged from 7-30 days and
there were no incidents of primary or secondary poisoning to
non-target species during the trial program.
Field trials completed outside the United States are
summarized in Tables 5 and 6 for R. norvegicus and Mmusculus respectively. Nine (9) R. norvegicus infestations
were treated with 0.005% or 0.01% bromethalin grain baits
in Switzerland, Denmark, England, Ireland and Brazil.
Average percent reduction in census feed consumption
ranged from 83 to 100% after 3 to 14 days of exposure to
bromethalin baits. Four (4) M. musculus populations were
treated with 0.01% bromethalin grain baits in France and
Switzerland. Average percent reduction in census feed con-
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Table 6. Field Trials with 0.01% Bromethalin Grain Formulations Against Infestations of M-musculus.

RODENTICIDE PEN TESTING
Test Procedure
An indoor pen test system was established so that indirect
comparisons of rodenticides could be made under similar
conditions. Indoor pens measuring 4x2x2 (8 m2) were con-

structed on a concrete base with stainless steel wire mesh. The
bottom of the pens was covered with approximately 10 cm of
saw dust and abundant harborage was provided in the form of
overturned plastic containers. Wild male and female Norway rats
were introduced into the pen and provided standard laboratory
diet and water ad libitum. Rodents were allowed to acclimate
for 10-12 weeks before testing and obviously dominant or
submissive animals were removed. Twelve (12) bait trays
containing either 2 kg of rodenticide or untreated grain were
distributed throughout the pen. The position of the bait trays was
alternated daily and consumption was measured. Dead animals
were removed when located. A diagram of the testing facility is
shown in Figure 1.
Fig. 3. Efficacy of 0.005% Bromadiolone oat baits in a pen trial with 92
wild Norway rats.

Fig. 1. Diagram of rodenticide test pens.

Comparative Rodenticide Tests
The objective of these tests was to compare the palatability and efficacy of bromethalin with leading secondgeneration anticoagulants under controlled conditions.
Results from tests with 0.01% bromethalin and C.005%
bromadiolone oat formulations and 0.005% brodifacoum
commercial pelleted formulations are presented in Figures 2,
3, and 4, respectively.

Fig. 4. Efficacy of 0.005% Brodifacoum pellets in a pen trial with 94
Norway rats.

A total of 836 g of untreated oats and 973 g of 0.01%
bromethalin oat baits were consumed by 125 R. norvegicus
in the bromethalin test pen over 6 days. This corresponds to
28.7 g of bromethalin bait/kg rat and 24.7 g untreated grain/
kg rat. Complete mortality was achieved by the sixth day of
baiting (x = 2.4 days).
In the bromadiolone test pen, a total of 1722 g of
untreated oats and 1628 g of 0.005% bromadiolone oat baits
were consumed by 92 R. norvegicus over 10 days. This
corresponds to 99.1 g of bromadiolone bait/kg rat and 93.7 g
untreated grain/kg rat. Complete mortality was achieved by
the 10th day of baiting (x = 5.5 days).
A total of 6615 g of untreated grain and 1442 g of 0.005%
brodifacoum pellets were consumed by 94 R. norvegicus
over the 10-day test period. This corresponds to 60.1 g of
brodifacoum bait/kg rat and 275.6 g of untreated grain/kg rat.
Incomplete mortality of 83% (78/94) was achieved after 10
days of baiting. Rats which survived after 6 days fed almost
exclusively on untreated grains rather than brodifacoum
pellets.

Fig. 2. Efficacy of 0.01% Bromethalin oat baits in a pen trial with 125
Norway rats.
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Results from these tests illustrate differences between
the two second-generation anticoagulants and bromethalin
based upon their respective modes of action and formulation
types. Rats continued to feed on the two anticoagulants over
the 10 day test period resulting in at least 2 to 3 times more
anticoagulant bait consumption and 3 to 11 times more
untreated grain consumption when compared to results from
the bromethalin test pen. Feed consumption in the bromethalin pen virtually stopped after 4 days, indicative of the
efficiency of bromethalin baiting under semi-natural conditions. Dead rodents were rapidly observed within 24 hours
after baiting with bromethalin and complete mortality was
achieved by the 6th day as compared to 10 days with
bromadiolone. Untreated grain was preferred over pelleted
brodifacoum formulations leading to incomplete mortality
with this product under these experimental conditions.
Overall, these results illustrate the quick kill and efficiency possible when utilizing bromethalin as an alternative
to anticoagulant rodenticides for controlling Norway rat
infestations.
CONCLUSIONS
The diphenylamine rodenticide bromethalin has been
thoroughly researched over the past decade and commercial
formulations have been safely used in and around buildings
in the United States over the past 3 years. International
development work has shown bromethalin to be effective
against susceptible and anticoagulant-resistant rodents. Data
required for European registrations are nearly complete and
will be submitted to authorities in selected countries throughout 1988. Bromethalin's quick kill and stop-feed action make
this rodenticide a highly efficient alternative to anticoagulants.
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